The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a recommended therapy for chronic myeloid leukemia (CML), typically as second or third-line treatment.
• The advent of tyrosine kinase inhibitors (TKIs) has led to a significant decrease in HSCT for CML in the chronic phase.
• Current recommendations primarily focus on disease risk, such as TKI failure, potentially overlooking other critical factors.

Purpose of the Study:

• To propose an updated, balanced appraisal of allogeneic HSCT for individual CML patients.
• To advocate for the integration of HSCT into treatment algorithms earlier in the disease course.
• To redefine the role of HSCT based on a comprehensive assessment of disease risk, transplant risk, and macroeconomic factors.

Main Methods:

• Review of current HSCT recommendations for chronic myeloid leukemia.
• Analysis of disease risk stratification in CML.
• Evaluation of transplant-related risks and macroeconomic considerations.

Main Results:

• The introduction of TKIs has significantly reduced HSCT utilization in chronic phase CML.
• Existing recommendations may not adequately address the evolving treatment landscape for CML.
• A more individualized approach considering disease and transplant risks is warranted.

Conclusions:

• HSCT should be considered earlier, particularly at the first TKI failure for high-risk CML patients with low transplant risk.
• For CML patients with very advanced disease and high transplant risk, HSCT may be best reserved for research settings.
• Updated guidelines are necessary to optimize HSCT utilization in chronic myeloid leukemia management.